Results 141 to 150 of about 36,345 (262)

Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib. [PDF]

Cancer
McKay RR, Xie W, Ajmera A, Araneta A, Folefac E, Hussain A, Kyriakopoulos CE, Olson A, Parikh M, Parikh R, Saraiya B, Shapiro GI.   +11 more
europepmc   +1 more source

From Association to Mechanism: Regulatory Annotation and Pathway Mapping of Genes Surrounding Breast Cancer Risk Variants

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Inherited factors account for a large share of breast cancer susceptibility, yet the biological consequences of most risk variants are still poorly understood. To address this gap, we studied 175 breast cancer risk variants confirmed by genome‐wide association studies and gathered the genes that lie near them.
Sultana Jannat, Trina Mitra, Nafisa Nawar Fariha, Tasmia Tabassum, Kulsuma Bahar Bethi, Synchita Majumder Kaya, Md. Arif Hossen, Md. Saad Hossain, Jobaier Ibne Deen, Mohammed Emon, Laila Khaleda, Md. Hridoy Ahmed   +11 more
wiley   +1 more source

Erratum: [Corrigendum] Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer. [PDF]

Oncol Lett
Chen X, Yin L, Qiao G, Li Y, Li B, Bai Y, Feng F.   +6 more
europepmc   +1 more source

Japanese Co‐Sleeping Practices Challenge French Migrant Mothers' Cultural Representations of Childcare

International Journal of Applied Psychoanalytic Studies, Volume 23, Issue 3, September 2026.
ABSTRACT This study explores the perspective of French migrant mothers in Japan toward co‐sleeping. Psychoanalytical theories attest that the pathogenicity of co‐sleeping practices relies on the meanings attributed to its cultural framework. In France, the practice of co‐sleeping is unusual and discouraged for children's well‐being.
Anne‐Sophie Mpacko, Yoko Hamada, Akiyoshi Okada   +2 more
wiley   +1 more source

CDK9 degrader induces BRCAness and sensitizes castration-resistant prostate cancer to PARP inhibitor. [PDF]

Theranostics
Li J, Sun J, Tan W, Li G, Xiao W, Wu J, Yang W, Chen C, Li Y, Liu J, Liu Y, Liu D, Chen XH, Zhu R, Huang R, Yan J.   +15 more
europepmc   +1 more source

Urethral Metastasis of Therapy‐Induced Neuroendocrine Prostate Cancer Successfully Managed With Chemoradiotherapy: A Case Report

IJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Urethral metastasis of prostate cancer is exceptionally rare, particularly in castration‐resistant disease. Therapy‐induced neuroendocrine prostate cancer (t‐NEPC) is an aggressive variant with limited treatment options. Case Presentation A 72‐year‐old man, 14 years after diagnosis of prostate adenocarcinoma treated with androgen ...
Toshiaki Kayaba, Satoshi Washino, Takanori Hayase, Kai Yazaki, Kimitoshi Saito, Tomoaki Miyagawa   +5 more
wiley   +1 more source

Androgen receptor reactivation in castration-resistant prostate cancer: mechanisms, epigenetic adaptation, and therapeutic vulnerabilities. [PDF]

Front Oncol
Guo J, Wu K, Ma Z, Guo S, Wang F, Lu L.
europepmc   +1 more source

Castration-Resistant Prostate Carcinoma [PDF]

, 2020
openaire   +1 more source

Penile Metastasis From Castration‐Resistant Prostate Cancer: A Case Report

IJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Penile metastasis from prostate cancer—generally associated with a poor prognosis—is rare and underreported. We report one relevant case. Case Presentation The patient was a 65‐year‐old male with metastatic hormone‐sensitive prostate cancer (prostate‐specific antigen [PSA]: 500 ng/mL) and lung, bone, and lymph node metastases. The
Satoshi Asakura, Yoshihiro Nakagami, Tatsuki Inoue, Yuki Matsui, Kazuhiko Oshinomi, Masakazu Nagata, Takashi Fukagai, Yasuyuki Ohira, Yoshiko Yamochi   +8 more
wiley   +1 more source

SLC3A1 Mitigates Ferroptosis and Promotes Enzalutamide Resistance in Prostate Cancer

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 9, September 2026.
SLC3A1 is a promising therapeutic target for advanced prostate cancer. ABSTRACT Prostate cancer (PCa) remains a leading cause of cancer‐related mortality in aging male, with resistance to enzalutamide (Enza) representing a major therapeutic challenge. This study identifies SLC3A1 as a key driver of Enza resistance.
Peng Liu, Haocheng Zhang, Yuhang Qian, Jiong Zhang, Xiaojun Deng, Bin Sun   +5 more
wiley   +1 more source